Is the clinical and regulatory update Mirati Therapeutics (MRTX) provided Monday for its lead lung cancer cancer immunotherapy drug really positive? That’s what the biotech chose to say in the headline of its press release. The details, disclosed for the first time, are far more concerning.

Mirati is one of many biotechs developing new immunotherapy drugs that are meant to combine with existing checkpoint inhibitors like Merck’s Keytruda or Bristol-Myers Squibb’s Opdivo. The idea is that combinations of immunotherapies will provide greater benefit to a larger group of patients than checkpoints can achieve on their own.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy